A central theme of the current program project relies on the ability to target specific dendritic cell subsets invivo to determine their functional properties in immunity and tolerance. In the past funding period a methodwas collectively developed that facilited this analysis through the use of specifically engineered monoclonalantibodies that recognized a DC-restricted surface marker and delivered a defined antigen to those cells.This method of DC targeting will be extensively utilized in all three projects in the next funding period todirect model antigens and authentic autoantigens to CD8+ and CDS- DC subsets in vivo. Monoclonalantibodies to DEC-205 and 33D1 will initially be modified to deliver antigens in vivo and further Fcengineered to direct binding of the antibody to either activation or inhibitory FcRs on the specific DC subset.During the past funding period efficient methods were developed to engineer the heavy chains of theseantibodies for antigen delivery and selective FcR binding. Transient transfection of the modified heavychain, together with the unmodified light chain into 293T cells resulted in expression of the chains, assemblyof the tetrameric antibody molecule and its secretion into the medium. We propose to centralize theseprocedures into a core facility to provide each laboratory with the necessary reagents to carry out theexperiments proposed. Such an approach will streamline the process of generating and expressing thesemodified and Fc engineered antibodies, reduce the redundancy of having each laboratory carry out thesesame procedures and insure reproducibility and quality. The facility will occupy 1,000 sq. ft of newlyrenovated space, fully equipped for mammalian cell culture propagation, protein isolation and purification.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
2P01AI051573-06
Application #
7300790
Study Section
Special Emphasis Panel (ZAI1-MP-I (J1))
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2007-07-15
Budget End
2008-06-30
Support Year
6
Fiscal Year
2007
Total Cost
$251,742
Indirect Cost
Name
Rockefeller University
Department
Type
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Sela, Uri; Park, Chae Gyu; Park, Andrew et al. (2016) Dendritic Cells Induce a Subpopulation of IL-12R?2-Expressing Treg that Specifically Consumes IL-12 to Control Th1 Responses. PLoS One 11:e0146412
Schreiber, Heidi A; Loschko, Jakob; Karssemeijer, Roos A et al. (2013) Intestinal monocytes and macrophages are required for T cell polarization in response to Citrobacter rodentium. J Exp Med 210:2025-39
Bozzacco, Leonia; Yu, Haiqiang (2013) Identification and quantitation of MHC class II-bound peptides from mouse spleen dendritic cells by immunoprecipitation and mass spectrometry analysis. Methods Mol Biol 1061:231-43
Guermonprez, Pierre; Helft, Julie; Claser, Carla et al. (2013) Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nat Med 19:730-8
Bozzacco, Leonia; Yu, Haiqiang; Dengjel, Jorn et al. (2012) Strategy for identifying dendritic cell-processed CD4+ T cell epitopes from the HIV gag p24 protein. PLoS One 7:e41897
Meredith, Matthew M; Liu, Kang; Kamphorst, Alice O et al. (2012) Zinc finger transcription factor zDC is a negative regulator required to prevent activation of classical dendritic cells in the steady state. J Exp Med 209:1583-93
Meredith, Matthew M; Liu, Kang; Darrasse-Jeze, Guillaume et al. (2012) Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. J Exp Med 209:1153-65
Wang, Bei; Zaidi, Neeha; He, Li-Zhen et al. (2012) Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res 14:R39
Bozzacco, Leonia; Yu, Haiqiang; Zebroski, Henry A et al. (2011) Mass spectrometry analysis and quantitation of peptides presented on the MHC II molecules of mouse spleen dendritic cells. J Proteome Res 10:5016-30
Li, Fubin; Ravetch, Jeffrey V (2011) Inhibitory Fc? receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333:1030-4

Showing the most recent 10 out of 40 publications